|
|
Article: Cubicin granted marketing approval in Europe; First-in-class antibiotic approved for treatment of complicated skin and soft-tissue infections; Imminent product launch in the UK and the Netherlands.
- Article from:
- M2 Presswire
- Article date:
- January 24, 2006
CopyrightCOPYRIGHT 2006 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-24 January 2006-Chiron Corporation: Cubicin granted marketing approval in Europe; First-in-class antibiotic approved for treatment of complicated skin and soft-tissue infections; Imminent product launch in the UK and the Netherlands(C)1994-2006 M2 COMMUNICATIONS LTD
RDATE:23012006
Chiron Corporation (Nasdaq:CHIR) today announced that the European Commission has granted marketing approval for CUBICIN(R) (daptomycin), a first-in-class IV antibiotic. The marketing approval was granted in the 25 member states of the European Union, Iceland, Liechtenstein and Norway. Under the approval, CUBICIN is indicated for the treatment of complicated skin ...